Keros Therapeutics Inc
NASDAQ:KROS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.55
21.84
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Relative Value
The Relative Value of one
KROS
stock under the Base Case scenario is
1.54
USD.
Compared to the current market price of 20.13 USD,
Keros Therapeutics Inc
is
Overvalued by 92%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
KROS Competitors Multiples
Keros Therapeutics Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Keros Therapeutics Inc
NASDAQ:KROS
|
613.4m USD | 2.5 | 9.5 | -1.8 | -1.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 873 393.2 | -160 995.2 | -195 499.5 | -193 268.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
400.9B USD | 6.7 | 170.7 | 16.5 | 23.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
176.1B USD | 4.9 | 25.1 | 18.1 | 18.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
154.4B USD | 5.3 | 19 | 12.8 | 12.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.9B USD | 9.9 | 31.5 | 23.1 | 24.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 079.8 | -530.7 | -577.9 | -562.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.8B USD | 5.7 | 17.6 | 16.8 | 19.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
84.8B AUD | 3.6 | 18.7 | 12.6 | 15.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
45B EUR | 14.6 | 34.4 | 59.4 | 61 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
53.3B USD | 16.6 | 1 224.5 | 160.9 | 195.2 |
